In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
14 authors.
David A G GervasioDepartment of Dermatology, School of Medicine, University of California San Diego.ORCID 0000-0001-8604-8897 Claire E TurkalDepartment of Dermatology, School of Medicine, University of California San Diego.
Michael X WangDepartment of Dermatology, School of Medicine, University of California San Diego.
Brandon E MauchDepartment of Dermatology, School of Medicine, University of California San Diego.
Michelle H PawDepartment of Dermatology, School of Medicine, University of California San Diego.
Mehrshad HairaniDepartment of Dermatology, School of Medicine, University of California San Diego.
Sophie H HarrisDepartment of Dermatology, School of Medicine, University of California San Diego.
Matthew J HangauerDepartment of Dermatology, School of Medicine, University of California San Diego.ORCID 0000-0002-5008-6696 Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MVirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MContemporary Approaches to Cancer Cell Signaling and CommunicationT32CA009523 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DONOGHUE, DANIEL J, YANG, JING · 1985 to 2025
$12.1MPredoctoral and Postdoctoral Training in Cancer Cell BiologyT32CA067754 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEAN Y.J. WANG · 1995 to 2026
$6.5MFunctional Networks for Persister Cell SensitivitiesR01CA212767 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCMANUS, MICHAEL T · 2017 to 2021
$2.6MIllumina NovaSeq 6000 Sequencing SystemS10OD026929 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JEPSEN, KRISTEN LYNN · 2019 to 2019
$600kNCI NIH HHS P30 CA023100NCI NIH HHS R01 CA212767NCI NIH HHS T32 CA009523NCI NIH HHS T32 CA067754NIAID NIH HHS P30 AI036214NIH HHS S10 OD026929
6 · The paper itselfAbstract
Oncogene targeted cancer therapies can provide deep responses but frequently suffer from acquired resistance.
Identifiers
PMID40894800
PMCPMC12393451
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390